Will Novartis’ Pasireotide Find A Simpler Road To Approval In Cushing’s?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With a mechanism of action more suited to the traditional endpoints in Cushing’s, and a randomized trial, the pasireotide review could be more straightforward than Korlym’s.